This article highlights about the role of inflammation and oncogenes activate inflammatory mediators in tumor progression.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Inflammation is the body’s defensive action against various stimuli such as physical or chemical or infectious agents.
📊
Key Findings & Data:If the inflammation aggravates chronically, non-resolved, dysregulated immune system, results release of various inflammatory mediators such as free radicals (ROS and RNS), cytokines, chemokines, growth factors and proteolytic enzymes produced by innate and adaptive immune cells activate transcriptional factors (NF-KB,STAT3 and HIF-1α) results in cell proliferation, angiogenesis, immunosuppression, genetic instability, invasion and metastasis.
💡
Conclusion & Impact:This article highlights about the role of inflammation and oncogenes activate inflammatory mediators in tumor progression.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Inflammation · cancer · lymphocytes
Abstract
Inflammation is the body’s defensive action against various stimuli such as physical or chemical or infectious agents. Acute inflammation and their mediators help in tissue repair and healing. If the inflammation aggravates chronically, non-resolved, dysregulated immune system, results release of various inflammatory mediators such as free radicals (ROS and RNS), cytokines, chemokines, growth factors and proteolytic enzymes produced by innate and adaptive immune cells activate transcriptional factors (NF-KB,STAT3 and HIF-1α) results in cell proliferation, angiogenesis, immunosuppression, genetic instability, invasion and metastasis. Oncogenes related to cancer activate inflammatory mediators such as chemokines and cytokines, which alters the inflammatory tumor microenvironment, promotes tumor progression. This article highlights about the role of inflammation and oncogenes activate inflammatory mediators in tumor progression.
T.G, S. (2018). Inflammation-related cancer or cancer-related inflammation. The European Research Journal, Cilt: 4 - Sayı: 1, 1–5. https://ajindex.com/articles/361302
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation and cancer. Cell 2010;140:883-99
Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015;125:3347-55
Maciel TT, Moura IC, Hermine O. The role of mast cells in cancers. F1000Prime Rep 2015;7:9
Shrihari TG. Dual role of inflammatory mediators in cancer. Ecancermedicalscience 2017;11:721
Korniluk A, Koper O, Kemona H, Dymicka-Piekarska V. From inflammation to cancer. Ir J Med Sci 2017:186;57-62
Okada F. Inflammation-related carcinogenesis: current findings epidemiological trends, causes and mechanisms. Yonago Acta Medica 2014:57:65-72
Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015;347:78-81
Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res 2011;317:664-73
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30:1073-81
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74
Chai EZ, Siveen KS, Shanmugam MK, Arfuso F, Sethi G. Analysis of the intricate relationship between chronic inflammation and cancer. Biochem J 2015;468:1-15
Katoh H, Watanabe M. Myeloid-derived suppressor cells and therapeutic strategies in cancer. Mediators Inflamm 2015;2015:159269
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014;41:49-61
Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M, Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer 2014;110:469-78
Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating ntigen-presenting cells critical for T cell immunity. Cancer Cell 2014;26:638-52
Houghton AM. The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 2010;9:1732-7
Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and c